Remedy: Excitement builds ahead of AW2 release

By Atte Riikola
Remedy's Q1 figures were weak as expected, with the company's 5 game projects in development this year mainly showing up as costs in the income statement. However, the company's investment story is about to enter an interesting phase with the release of Alan Wake 2 at the end of the year, which will also be a key short-term driver for the stock. At the current valuation, we continue to take a cautiously positive view towards the game's release.